Followed Journals
Journal you Follow: 0
 
Sign Up to follow journals, search in your chosen journals and, optionally, receive Email Alerts when new issues of your Followed Journals are published.
Already have an account? Sign In to see the journals you follow.
Similar Journals
Journal Cover
JAMA The Journal of the American Medical Association
Journal Prestige (SJR): 8.876
Citation Impact (citeScore): 7
Number of Followers: 2592  
 
  Full-text available via subscription Subscription journal
ISSN (Print) 0098-7484 - ISSN (Online) 1538-3598
Published by American Medical Association Homepage  [14 journals]
  • Audio Highlights

    • Free pre-print version: Loading...

      Abstract: Listen to the JAMA Editor’s Audio Summary for an overview and discussion of the important articles appearing in this week’s issue of JAMA.
      PubDate: Tue, 21 Sep 2021 00:00:00 GMT
      DOI: 10.1001/jama.2020.18133
      Issue No: Vol. 326, No. 11 (2021)
       
  • JAMA

    • Free pre-print version: Loading...

      Pages: 993 - 994
      PubDate: Tue, 21 Sep 2021 00:00:00 GMT
      DOI: 10.1001/jama.2020.18131
      Issue No: Vol. 326, No. 11 (2021)
       
  • Twenty Years After 9/11, Responders Are Still Healing

    • Free pre-print version: Loading...

      Authors: Abbasi J.
      Pages: 995 - 998
      Abstract: This Medical News article discusses ongoing physical and mental health effects for emergency personnel, recovery and cleanup workers, and volunteers who responded on and after the September 11, 2001, terrorist attacks.
      PubDate: Tue, 21 Sep 2021 00:00:00 GMT
      DOI: 10.1001/jama.2021.14010
      Issue No: Vol. 326, No. 11 (2021)
       
  • Increase in Myopia Reported Among Children During COVID-19 Lockdown

    • Free pre-print version: Loading...

      Authors: Kuehn BM.
      Pages: 999 - 999
      Abstract: Spending less time outdoors and more hours looking at screens during the COVID-19 pandemic contributed to an increase in myopia among children in Hong Kong, an ongoing prospective study reported.
      PubDate: Tue, 21 Sep 2021 00:00:00 GMT
      DOI: 10.1001/jama.2021.14475
      Issue No: Vol. 326, No. 11 (2021)
       
  • India Takes Aim at Eliminating Visceral Leishmaniasis

    • Free pre-print version: Loading...

      Authors: Kuehn BM.
      Pages: 999 - 999
      Abstract: India is opening 4 centers of excellence to help train health care workers and improve treatment for complicated visceral leishmaniasis cases as part of an ongoing effort to eliminate the disease, according to a World Health Organization report.
      PubDate: Tue, 21 Sep 2021 00:00:00 GMT
      DOI: 10.1001/jama.2021.15467
      Issue No: Vol. 326, No. 11 (2021)
       
  • US Health System Ranks Last Among High-Income Countries

    • Free pre-print version: Loading...

      Authors: Kuehn BM.
      Pages: 999 - 999
      Abstract: The US spends more of its gross domestic product (GDP) on health care than other high-income countries yet ranks last in access to care, administrative efficiency, equity, and health care outcomes, according to an analysis by the nonprofit Commonwealth Fund.
      PubDate: Tue, 21 Sep 2021 00:00:00 GMT
      DOI: 10.1001/jama.2021.15468
      Issue No: Vol. 326, No. 11 (2021)
       
  • Lupus Drug Is Approved Despite Previous Clinical Trial Setback

    • Free pre-print version: Loading...

      Authors: Kuehn BM.
      Pages: 1000 - 1000
      Abstract: The FDA has approved anifrolumab-fnia for patients with systemic lupus erythematosus (SLE) even though the initial phase 3 trial results showed the drug didn’t outperform placebo in meeting its primary end point.
      PubDate: Tue, 21 Sep 2021 00:00:00 GMT
      DOI: 10.1001/jama.2021.14964
      Issue No: Vol. 326, No. 11 (2021)
       
  • New Treatment Approved for Adults and Children With Pompe Disease

    • Free pre-print version: Loading...

      Authors: Kuehn BM.
      Pages: 1000 - 1000
      Abstract: A second enzyme replacement treatment has received approval for the treatment of late-onset Pompe disease in patients aged 1 year or older.
      PubDate: Tue, 21 Sep 2021 00:00:00 GMT
      DOI: 10.1001/jama.2021.15588
      Issue No: Vol. 326, No. 11 (2021)
       
  • “Collaborative Communities” Tackle Device Development
           Challenge

    • Free pre-print version: Loading...

      Authors: Kuehn BM.
      Pages: 1000 - 1000
      Abstract: The FDA’s Center for Devices and Radiological Health is participating in a growing number of public-private partnerships called “collaborative communities” that focus on overcoming device development hurdles.
      PubDate: Tue, 21 Sep 2021 00:00:00 GMT
      DOI: 10.1001/jama.2021.15589
      Issue No: Vol. 326, No. 11 (2021)
       
  • Confronting the Delta Variant of SARS-CoV-2

    • Free pre-print version: Loading...

      Authors: del Rio C; Malani PN, Omer SB.
      Pages: 1001 - 1002
      Abstract: This Viewpoint discusses the Delta variant of SARS-CoV-2, including its epidemiology, transmissibility, how uneven vaccination coverage in the US encouraged its spread, and the most effective public health responses to curb it.
      PubDate: Tue, 21 Sep 2021 00:00:00 GMT
      DOI: 10.1001/jama.2021.14811
      Issue No: Vol. 326, No. 11 (2021)
       
  • Potential Implications of SARS CoV-2 Delta Variant Surges for Rural Areas
           and Hospitals

    • Free pre-print version: Loading...

      Authors: Kadri SS; Simpson SQ.
      Pages: 1003 - 1004
      Abstract: This Viewpoint discusses the Delta variant of SARS-CoV-2 and suggests potential solutions for institutions, governments, and society as they navigate the potentially rural-dominant surge in infections.
      PubDate: Tue, 21 Sep 2021 00:00:00 GMT
      DOI: 10.1001/jama.2021.13941
      Issue No: Vol. 326, No. 11 (2021)
       
  • The Helping to End Addiction Long-term Initiative of the National
           Institutes of Health

    • Free pre-print version: Loading...

      Authors: Baker RG; Koroshetz WJ, Volkow ND.
      Pages: 1005 - 1006
      Abstract: This Viewpoint discusses the Helping to End Addiction Long-term initiative of the National Institutes of Health that was launched in 2018 to provide scientific solutions to the evolving crisis of opioid misuse, addiction, and overdose.
      PubDate: Tue, 21 Sep 2021 00:00:00 GMT
      DOI: 10.1001/jama.2021.13300
      Issue No: Vol. 326, No. 11 (2021)
       
  • It Is What It Is

    • Free pre-print version: Loading...

      Authors: Kerlin M.
      Pages: 1007 - 1008
      Abstract: In this narrative medicine essay, a critical care physician tells how plans for her sister’s kidney transplant halted last year when the COVID-19 pandemic caused the shutdown of most nonurgent medical care services and hopes the system can develop a better process for patients with chronic diseases.
      PubDate: Tue, 21 Sep 2021 00:00:00 GMT
      DOI: 10.1001/jama.2021.14917
      Issue No: Vol. 326, No. 11 (2021)
       
  • Transcatheter Valve Replacement for Bicuspid Aortic Stenosis

    • Free pre-print version: Loading...

      Authors: Otto CM; Newby DE.
      Pages: 1009 - 1010
      Abstract: Bicuspid aortic valve (BAV) disease is a congenital condition that affects an estimated 1% of the world’s population. While initial valve function is relatively normal and has little early clinical consequence, progressive valve fibrosis and calcification eventually results in severe aortic stenosis, requiring aortic valve replacement in nearly all patients with BAV in later life.
      PubDate: Tue, 21 Sep 2021 00:00:00 GMT
      DOI: 10.1001/jama.2021.13229
      Issue No: Vol. 326, No. 11 (2021)
       
  • A Reporting Guideline for Mediation Analyses

    • Free pre-print version: Loading...

      Authors: Yadav K; Lewis RJ.
      Pages: 1011 - 1012
      Abstract: In this issue of JAMA, Lee et al provide the results of a carefully structured, comprehensive effort to define the elements to be included in reports of studies using mediation analyses. Mediation analysis refers to a group of statistical methods for assessing the relative contributions of multiple pathways by which a treatment or risk factor may affect clinical outcomes. Mediators are quantifiable characteristics in the causal pathway through which an intervention (such as a treatment) exerts its effect. For example, if a behavioral intervention leads to reduced caloric intake, and patients lose weight as a result, then caloric intake would be a likely mediator of the effect of the behavioral intervention on weight loss. A mediation analysis evaluates the relationships between the treatment and potential mediators and, separately, between the mediators and outcomes, and quantitatively partitions the overall treatment effect among the different causal pathways. One of the causal pathways may be direct without any identified mediator.
      PubDate: Tue, 21 Sep 2021 00:00:00 GMT
      DOI: 10.1001/jama.2021.15462
      Issue No: Vol. 326, No. 11 (2021)
       
  • Lower Tidal Volume Using Extracorporeal Carbon Dioxide Removal in Acute
           Hypoxemic Respiratory Failure

    • Free pre-print version: Loading...

      Authors: McNamee JJ; Gillies MA, Barrett NA, et al.
      Pages: 1013 - 1023
      Abstract: This randomized clinical trial examines whether lower tidal volume ventilation facilitated by extracorporeal carbon dioxide removal, compared with standard care, will decrease mortality 90 days after randomization in patients with acute hypoxemic respiratory failure.
      PubDate: Tue, 21 Sep 2021 00:00:00 GMT
      DOI: 10.1001/jama.2021.13374
      Issue No: Vol. 326, No. 11 (2021)
       
  • Effect of Probiotics on Incident Ventilator-Associated Pneumonia

    • Free pre-print version: Loading...

      Authors: Johnstone J; Meade M, Lauzier F, et al.
      Pages: 1024 - 1033
      Abstract: This clinical trial assessed whether Lactobacillus rhamnosus GG compared with placebo reduces ventilator-associated pneumonia and other clinically important outcomes for a broad range of critically ill patients.
      PubDate: Tue, 21 Sep 2021 00:00:00 GMT
      DOI: 10.1001/jama.2021.13355
      Issue No: Vol. 326, No. 11 (2021)
       
  • TAVR for Bicuspid Aortic Valve Stenosis

    • Free pre-print version: Loading...

      Authors: Makkar RR; Yoon S, Chakravarty T, et al.
      Pages: 1034 - 1044
      Abstract: This registry-based cohort study compared rates of mortality and stroke at 30 days and 1 year among patients at low surgical risk with bicuspid vs tricuspid aortic stenosis undergoing transcatheter aortic valve replacement (TAVR).
      PubDate: Tue, 21 Sep 2021 00:00:00 GMT
      DOI: 10.1001/jama.2021.13346
      Issue No: Vol. 326, No. 11 (2021)
       
  • A Guideline for Reporting Mediation Analyses of Randomized Trials and
           Observational Studies

    • Free pre-print version: Loading...

      Authors: Lee H; Cashin AG, Lamb SE, et al.
      Pages: 1045 - 1056
      Abstract: This Special Communication describes the methods that were used to develop the guideline, provides a long- and short-form checklist to be used when writing research reports, presents brief explanations for each reporting item, and provides guidance on how to use A Guideline for Reporting Mediation Analyses (AGReMA).
      PubDate: Tue, 21 Sep 2021 00:00:00 GMT
      DOI: 10.1001/jama.2021.14075
      Issue No: Vol. 326, No. 11 (2021)
       
  • Reporting Findings From Mediation Analyses

    • Free pre-print version: Loading...

      Authors: Fontanarosa PB.
      Pages: 1057 - 1057
      Abstract: In this issue of JAMA, Lee and colleagues present A Guideline for Reporting Mediation Analyses of Randomized Trials and Observational Studies: The AGReMA Statement. This consensus-based guidance was developed using the Enhancing Quality and Transparency of Health Research (EQUATOR) framework for developing reporting guidelines. As with other reporting guidelines, use of the AGReMA statement (including the 25-item checklist) by authors could help ensure that the information reported in manuscripts and in published articles based on mediation analyses is complete, accurate, transparent, and reproducible.
      PubDate: Tue, 21 Sep 2021 00:00:00 GMT
      DOI: 10.1001/jama.2021.15786
      Issue No: Vol. 326, No. 11 (2021)
       
  • ASCO Guidelines on Prevention and Management of Chemotherapy-Induced
           Peripheral Neuropathy

    • Free pre-print version: Loading...

      Authors: Derman BA; Davis AM.
      Pages: 1058 - 1059
      Abstract: This JAMA Clinical Guidelines Synopsis summarizes the American Society of Clinical Oncology’s 2020 guideline on the prevention and management of chemotherapy-induced peripheral neuropathy in adults.
      PubDate: Tue, 21 Sep 2021 00:00:00 GMT
      DOI: 10.1001/jama.2021.7458
      Issue No: Vol. 326, No. 11 (2021)
       
  • Pitolisant (Wakix) for Narcolepsy

    • Free pre-print version: Loading...

      Pages: 1060 - 1061
      Abstract: This Medical Letter review summarizes the use of pitolisant, a histamine-3–receptor antagonist/inverse agonist, for treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy.
      PubDate: Tue, 21 Sep 2021 00:00:00 GMT
      DOI: 10.1001/jama.2021.1349
      Issue No: Vol. 326, No. 11 (2021)
       
  • Antibody Response After Third mRNA-1273 SARS-CoV-2 Vaccine Dose in Kidney
           Transplant Recipients

    • Free pre-print version: Loading...

      Authors: Benotmane I; Gautier G, Perrin P, et al.
      Pages: 1063 - 1065
      Abstract: This study examines the antibody responses to a third dose (100 μg) of the mRNA-1273 SARS-CoV-2 vaccine among kidney transplant recipients in France who had not responded to 2 doses of the vaccine.
      PubDate: Tue, 21 Sep 2021 00:00:00 GMT
      DOI: 10.1001/jama.2021.12339
      Issue No: Vol. 326, No. 11 (2021)
       
  • Change in Saliva RT-PCR Sensitivity Over the Course of SARS-CoV-2
           Infection

    • Free pre-print version: Loading...

      Authors: Congrave-Wilson Z; Lee Y, Jumarang J, et al.
      Pages: 1065 - 1067
      Abstract: This study investigates the timeframe that optimizes saliva sensitivity for SARS-CoV-2 detection using reverse transcriptase–polymerase chain reaction (RT-PCR) testing.
      PubDate: Tue, 21 Sep 2021 00:00:00 GMT
      DOI: 10.1001/jama.2021.13967
      Issue No: Vol. 326, No. 11 (2021)
       
  • Therapeutic Drug Monitoring vs Standard Therapy During Infliximab
           Induction in Patients With Chronic Immune-Mediated Inflammatory Diseases

    • Free pre-print version: Loading...

      Authors: Papamichail K; Dubinsky MC, Cheifetz AS.
      Pages: 1067 - 1068
      Abstract: To the Editor NOR-DRUM Part A is the first randomized clinical trial to investigate the role of proactive therapeutic drug monitoring (TDM) during initiation of infliximab therapy in adults with various immune-mediated inflammatory disorders. The primary end point of clinical remission at week 30 did not differ significantly between the proactive TDM and standard therapy groups. The subset of patients with inflammatory bowel disease (IBD) had a similar outcome for the primary study end point as well as for numerous secondary outcomes.
      PubDate: Tue, 21 Sep 2021 00:00:00 GMT
      DOI: 10.1001/jama.2021.11477
      Issue No: Vol. 326, No. 11 (2021)
       
  • Therapeutic Drug Monitoring vs Standard Therapy During Infliximab
           Induction in Patients With Chronic Immune-Mediated Inflammatory Diseases

    • Free pre-print version: Loading...

      Authors: Serkland T; Skrede S, Berg J.
      Pages: 1068 - 1069
      Abstract: To the Editor We have several concerns about NOR-DRUM Part A. By using the term therapeutic drug monitoring, the authors placed this trial in a clinical pharmacological context, implying evaluation and adjustment of drug treatment through both clinical observation and drug concentration measurement. In the NOR-DRUM intervention group, however, according to our interpretation of the protocol, no dose adjustments were made if the serum concentration of the study drug was within the target range. The standard therapy group in this study may have benefitted from dose adjustments according to clinical assessment, while the intervention group did not receive dose adjustments if the study drug serum concentration was within the target range, even if there was suboptimal clinical effect. Because the target range is population based, it cannot be applied in a predictive manner for an individual. With a true TDM approach, particularly with concentrations at the lower end of the target range, a dose increase should be considered, as mentioned in the Limitations section of the article. If a patient benefits from an increase in drug dose, the accompanying serum level could represent a personalized target concentration for later use.
      PubDate: Tue, 21 Sep 2021 00:00:00 GMT
      DOI: 10.1001/jama.2021.11471
      Issue No: Vol. 326, No. 11 (2021)
       
  • Therapeutic Drug Monitoring vs Standard Therapy During Infliximab
           Induction in Patients With Chronic Immune-Mediated Inflammatory Diseases

    • Free pre-print version: Loading...

      Authors: Le Tilly O; Paintaud G, Ternant D.
      Pages: 1069 - 1069
      Abstract: To the Editor The conclusion of the recently published NOR-DRUM Part A is that compared with standard care, proactive TDM of infliximab had no significant effect on clinical remission assessed 30 weeks after treatment initiation.
      PubDate: Tue, 21 Sep 2021 00:00:00 GMT
      DOI: 10.1001/jama.2021.11474
      Issue No: Vol. 326, No. 11 (2021)
       
  • Therapeutic Drug Monitoring vs Standard Therapy During Infliximab
           Induction in Patients With Chronic Immune-Mediated Inflammatory
           Diseases—Reply

    • Free pre-print version: Loading...

      Authors: Syversen S; Bolstad N, Haavardsholm EA.
      Pages: 1069 - 1070
      Abstract: In Reply In response to our study on TDM during infliximab induction, 3 letters address different aspects of the study design. Dr Papamichail and colleagues propose that subpopulations of patients with IBD may benefit from higher drug levels than recommended by the study algorithm. Our therapeutic range was based on data available when the study was being planned and after consultation with key opinion leaders on the international advisory board. The therapeutic range in NOR-DRUM Part A is consistent with prior studies and treatment guidelines. We cannot exclude additional benefit from higher infliximab levels on endoscopic remission in IBD subpopulations as suggested by Papamichail and colleagues based on cross-sectional postinduction data, but we await data from prospective studies.
      PubDate: Tue, 21 Sep 2021 00:00:00 GMT
      DOI: 10.1001/jama.2021.11480
      Issue No: Vol. 326, No. 11 (2021)
       
  • Antimicrobial Therapy and Respiratory Hospitalization or Death in Adults
           With Idiopathic Pulmonary Fibrosis

    • Free pre-print version: Loading...

      Authors: Chen C; Wang C, Lai C.
      Pages: 1070 - 1071
      Abstract: To the Editor Of the 513 patients with idiopathic pulmonary fibrosis (IPF) in the CleanUP-IPF trial, 128 were randomized to receive co-trimoxazole; 126, doxycycline; and 259, usual care. After a mean follow-up of 13.1 months, there was no difference in the primary outcome (time to first nonelective respiratory hospitalization or all-cause mortality) between the groups. Based on this finding, the addition of co-trimoxazole or doxycycline to usual care was not recommended for patients with IPF. However, we have 2 concerns with this conclusion.
      PubDate: Tue, 21 Sep 2021 00:00:00 GMT
      DOI: 10.1001/jama.2021.11810
      Issue No: Vol. 326, No. 11 (2021)
       
  • Antimicrobial Therapy and Respiratory Hospitalization or Death in Adults
           With Idiopathic Pulmonary Fibrosis—Reply

    • Free pre-print version: Loading...

      Authors: Martinez FJ; Anstrom KJ, Noth I.
      Pages: 1071 - 1072
      Abstract: In Reply Dr Chen and colleagues raise important questions regarding the interpretation of the data published by the CleanUP-IPF investigative group. Two specific points require additional discussion.
      PubDate: Tue, 21 Sep 2021 00:00:00 GMT
      DOI: 10.1001/jama.2021.11813
      Issue No: Vol. 326, No. 11 (2021)
       
  • Incorrect Group Sizes in Figure

    • Free pre-print version: Loading...

      Pages: 1072 - 1072
      Abstract: In the US Preventive Services Task Force report titled “Counseling and Behavioral Interventions for Healthy Weight and Weight Gain in Pregnancy: Evidence Report and Systematic Review for the US Preventive Services Task Force,” published in the May 25, 2021, issue of JAMA, group sizes appeared incorrectly in a figure. In the “Obese” section of Figure 3, in the row reporting data for the study by Daly et al, the number of participants in the treatment group should have been 34, rather than 33, and the number in the control group should have been 42, rather than 36. This article was corrected online.
      PubDate: Tue, 21 Sep 2021 00:00:00 GMT
      DOI: 10.1001/jama.2021.14582
      Issue No: Vol. 326, No. 11 (2021)
       
  • Addition of Nonauthor Collaborator Names of the VICTAS Trial

    • Free pre-print version: Loading...

      Pages: 1072 - 1072
      Abstract: The Original Investigation titled “Effect of Vitamin C, Thiamine, and Hydrocortisone on Ventilator- and Vasopressor-Free Days in Patients With Sepsis: The VICTAS Randomized Clinical Trial,” published in the February 23, 2021, issue of JAMA, has been updated to include the nonauthor collaborator (group) names in a supplement. This article was corrected online.
      PubDate: Tue, 21 Sep 2021 00:00:00 GMT
      DOI: 10.1001/jama.2021.15080
      Issue No: Vol. 326, No. 11 (2021)
       
  • Penned

    • Free pre-print version: Loading...

      Authors: Uzgiris R.
      Pages: 1074 - 1074
      Abstract: Blue glyphs snake Over belly’s bulge:
      PubDate: Tue, 21 Sep 2021 00:00:00 GMT
      DOI: 10.1001/jama.2021.10994
      Issue No: Vol. 326, No. 11 (2021)
       
  • Beethoven’s Deafness

    • Free pre-print version: Loading...

      Pages: 1075 - 1075
      Abstract: Neither the practice nor the science of medicine, nor for that matter medical history, would be perceptibly affected by the knowledge or ignorance of what caused Beethoven’s deafness. Nevertheless, the mystery of this retrospective diagnosis has held the interest of many investigators. The interest continues to the present day, as evidenced by the recent publication of two conflicting viewpoints on the subject within one month of each other.
      PubDate: Tue, 21 Sep 2021 00:00:00 GMT
      DOI: 10.1001/jama.2020.18134
      Issue No: Vol. 326, No. 11 (2021)
       
  • MD-Granting Medical Schools in the United States, 2020-2021

    • Free pre-print version: Loading...

      Authors: Barzansky B; Etzel SI.
      Pages: 1077 - 1087
      Abstract: This Appendix presents data from the 2020-2021 Liaison Committee on Medical Education (LCME) annual questionnaire, which provides information on the number of students, student demographics, and curriculum content at US medical schools.
      PubDate: Tue, 21 Sep 2021 00:00:00 GMT
      DOI: 10.1001/jama.2021.12944
      Issue No: Vol. 326, No. 11 (2021)
       
  • Graduate Medical Education, 2020-2021

    • Free pre-print version: Loading...

      Authors: Brotherton SE; Etzel SI.
      Pages: 1088 - 1110
      Abstract: This Appendix presents 2020 National GME Census data detailing the numbers and types of ACGME-accredited training programs and the residents and fellows in them.
      PubDate: Tue, 21 Sep 2021 00:00:00 GMT
      DOI: 10.1001/jama.2021.13501
      Issue No: Vol. 326, No. 11 (2021)
       
  • Patient Information: Pulmonary Hypertension

    • Free pre-print version: Loading...

      Authors: Walter K.
      Pages: 1116 - 1116
      Abstract: This JAMA Patient Page describes the 5 different types of pulmonary hypertension and how it is diagnosed and treated.
      PubDate: Tue, 21 Sep 2021 00:00:00 GMT
      DOI: 10.1001/jama.2021.11054
      Issue No: Vol. 326, No. 11 (2021)
       
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
 


Your IP address: 35.172.203.87
 
Home (Search)
API
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-